A combination therapy of Ramucirumab and Paclitazel as second-line treatment for elderly gastric cancer patients: A exploratory phase II research

A combination therapy of Ramucirumab and Paclitazel as second-line treatment for elderly gastric cancer patients: A exploratory phase II research - A combination therapy of Ramucirumab and Paclitazel for elderly gastric cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023515

Enrollment

Registered

2016-12-01

Start date

2016-08-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histrogically proven adenocarcinoma 2. Advanced gastric cancer 3. Failure after first-line treatment 4. No massive ascites 5. No cerebrovascular disease 6. Possible oral intake 7. PS: 0 or 1 8. No lethal disfunction of the major organs 9. who gave informed consent

Exclusion criteria

Exclusion criteria: 1. Unconrollable DM 2. VTE 3. MoI 4. Cerebrovascular disease 5. No GI tract bleeding or perforation 6. Uncontrollable hypertension 7. Inappropriate patient for study

Design outcomes

Primary

Measure	Time frame
Toxicity	—

Secondary

Measure	Time frame
Response rate, PFS, OS	—

Countries

Japan

Contacts

Public ContactChikara Kunisaki

Medical Center, Yokohama City University Dept. of Surg., Gastroenterological Center

s0714@med.yokohama-cu.ac.jp045-261-5656

Outcome results